GT Biopharma (GTBP) Cash & Equivalents (2009 - 2026)
GT Biopharma (GTBP) reported Cash & Equivalents of $4.96 million for Q2 2026, down 5.1% from $5.23 million a year earlier and down 44.4% from the prior quarter.
Powered by 
Analysis
GT Biopharma (GTBP) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, GT Biopharma posted Cash & Equivalents of $6.81 million, up 72.4% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of 5.2% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $3.95 million in FY2024 (+266.2%), $1.08 million in FY2023 (-81.0%), $5.67 million in FY2022 (-36.8%) and $8.97 million in FY2021 (+69.3%).
- Five-year quarterly Cash & Equivalents spans a low of $1.08 million in Q4 2023 and a high of $9.68 million in Q3 2021.
- Year over year, Cash & Equivalents gained in five of the last eight quarters, with growth averaging 83.8%.
- The high point for year-over-year Cash & Equivalents in five years was Q1 2026 (growth of 277.3%); the low point was Q2 2022 (a decline of 86.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $8.92 million (Q1 2026), $6.81 million (Q4 2025) and $2.53 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 4.89 Bn |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 10.77 Bn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 9.55 Bn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | 400.00 Mn |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 7.94 Bn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 13.19 Bn |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 6.44 Bn |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 1.82 Bn |
| 10 | GT Biopharma | 6.65 Mn | -16.58 Mn | - | 4.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.96 Mn |
| Mar 31, 2026 | 8.92 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 5.23 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 3.95 Mn |
| Sep 30, 2024 | 6.42 Mn |
| Jun 30, 2024 | 9.25 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 5.67 Mn |
| Sep 30, 2022 | 2.47 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | 7.29 Mn |
| Dec 31, 2021 | 8.97 Mn |
| Sep 30, 2021 | 9.68 Mn |
API Access
GT Biopharma Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GTBP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "GTBP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GTBP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();